Skip to main content
. Author manuscript; available in PMC: 2013 Dec 15.
Published in final edited form as: Anal Biochem. 2012 Sep 18;431(2):84–89. doi: 10.1016/j.ab.2012.09.010

Fig.3.

Fig.3

The TR–FRET assay follows competitive inhibition mediated by IgE-Fc and FcεRIα-specific ligands. (A) Inhibition with FcεRIα lacking a His tag. Here, 25 nM AF488-Fc premixed with increasing concentrations of FcεRIα lacking a His tag (0– 200 nM) was tested in the presence of 15 nM FcεRIα and 5 nM Tb-Ab. (B) Inhibition with anti-IgE omalizumab (Xolair). Here, 25 nM AF488-Fc premixed with increasing concentrations of Xolair (0–200 nM) was tested in the presence of 15 nM FcεRIα and 5 nM Tb-Ab. (C) Inhibition with the IgE-Fc ligand DARPin E2_79. Here, 25 nM AF488-Fc premixed with increasing concentrations of E2_79 (0–200 nM) was tested in the presence of 15 nM FcεRIα and 5 nM Tb-Ab. (D) Inhibition with anti-FcεRIα Mab15-1. Here, 25 nM AF488-Fc was tested in the presence of 15 nM FcεRIα and 5 nM Tb-Ab premixed with increasing concentrations of mAb15.1 (0–200 nM).